SIGUIENTE ... : " IDEAYA BIOSCIENCES HA INICIADO UNA COLABORACIÓN CLÍNICA Con ASTRAZENECA " Para Probar el Conjugado Anticuerpo-Fármaco en Fase de Investigación IDE849 , Dirigido Contra la Proteína DLL3 TOP1 , Junto Con el Inhibidor de PD-L1 DURVALUMAB ( IMFINZI de ASTRAZENECA ) , en PACIENTES con SMALL CELL LUNG CANCER EXTENSIVE-STAGE .... ¿ PORQUE NO ELIGIERON AL ATEZOLIZUMAB ... ?
03 junio 2007
Sylentis ( Zeltia Group ) .
Imagine the next time you join a discussion about Sylentis. When you start sharing the fascinating Sylentis facts, your friends will be absolutely amazed. The information about Sylentis presented here will do one of two things: either it will reinforce what you know about Sylentis or it will teach you something new. Both are good outcomes. It never hurts to be well-informed with the latest on Sylentis. Compare what you've learned here to future articles so that you can stay alert to changes in the area of Sylentis.
Suscribirse a:
Comentarios (Atom)